We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Tuberculosis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Tuberculosis (TB) is a deadly infectious disease that affects the lungs of millions worldwide, and kills more people than HIV per year. In addition, one-third of the world’s population is infected with the TB bacteria, but is otherwise healthy-this state is called latent tuberculosis infection (LTBI), and can progress to TB disease sometimes.
Depending on how one’s immune system responds to it, exposure to the TB bacteria (through contact with someone with TB disease), can result in different outcomes. Half of the people exposed to the TB bacteria are resistant to it and do not get infected, while the other half develop LTBI, which can progress to TB disease in 5-15% cases (highest risk in the first 5 years after infection, after which the risk reduces).
The exact mechanisms of interaction between the immune system and the TB bacteria that result in the above states are not known, which is why our toolkit for tackling TB is limited and ancient (for example, the BCG vaccine dates back to 1921 and the Tuberculin Skin Test to 1907). Understanding the body’s immune response in the different states following TB exposure is therefore essential for developing effective TB control tools.
This study will describe immune responses to TB by looking to see which genes are switched on or off, which proteins appear or disappear, and how the immune cells change physically in people at the different states across the TB exposure spectrum. This will help us understand how the body’s immune system fights TB infection, why some people who are exposed get infected whilst others remain uninfected, and why only some people who have a TB infection develop disease. This will in turn help us make new and more accurate tests to diagnose of TB and better vaccines to protect people from tuberculosis.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
For all arms of research: • Any current or previous condition/circumstance that, in the opinion of the investigator, may put the individual at risk. • Those aged below 16 and above 65 years of age Specifically for those consenting to Research Bronchoscopy: • Smokers (current and ex-smokers who smoked within the last ten years) • Concomitant respiratory disease such as asthma and COPD • HIV infection • Any condition causing immunosuppression • Pregnancy
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Ajit
Lalvani
a.lalvani@imperial.ac.uk
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 35193
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
